Statistics from Altmetric.com
If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.
Marshall I. Zinc for the common cold. Cochrane Review, latest version 15 Feb 1999. In: The Cochrane Library. Oxford: Update Software.
Are zinc lozenges efficacious in reducing the incidence, severity, and duration of cold symptoms?
Studies were identified by searching MEDLINE (1966 to 1997), EMBASE/Excerpta Medica (1974 to 1997), and the Cochrane Library. Bibliographies of relevant papers were searched to identify unpublished trials.
Randomized, double-blind, placebo-controlled trials were selected if they evaluated interventions that began within 3 days of development of cold symptoms and compared treatment with zinc or placebo lozenges taken every 1.5 to 2 hours during waking hours for more than 6 h/d for a duration of 5 consecutive days. Outcomes had to include incidence and severity of throat and nasal symptoms and cough.
Data were extracted on study methods, participants, intervention, and outcomes. Methodologic quality of studies (selection, performance, exclusion, and detection bias) was assessed by 2 reviewers using 11 criteria; each study was rated as having high, medium, or low quality.
7 trials (n = 754) met the inclusion criteria. All were rated as having medium-to-high methodologic quality. 5 trials involved participants with community-acquired infections, and 2 trials involved volunteers who were experimentally inoculated with human rhinovirus. Data for most outcomes could not be pooled because of study differences. Pooled analyses were based on intention-to-treat results and used a fixed-effects model. After 3 days of treatment, no difference was found between zinc and placebo for the proportion of patients with symptoms (3 studies, n = 419) (Table). The results for symptomatic patients after 5 days (3 studies) and after 7 days (5 studies) of treatment were heterogeneous, and therefore the pooled results were deemed inappropriate. However, pooled results for 2 of 5 studies (n = 187) did show that fewer patients in the zinc group had cold symptoms after 7 days of treatment (Table).
Insufficient evidence exists to support the efficacy of zinc lozenges for reduction of the incidence, severity, and duration of cold symptoms.
Source of funding: No external funding.
For correspondence: Mr. I. Marshall, National Center of Epidemiology and Population Health, Australian National University, Canberra, Australia, 0200. FAX 61-2-62490740.
Abstract and Commentary also published in ACP Journal Club. 1999;131:69.
Zinc vs placebo for cold symptoms*
Treatment duration Weighted event rates RRR (95% CI) NNT (CI)
3 days 72.0% 72.6% 1% (11 to 12) Not significant
7 days 14.9% 48.9% 69% (48 to 82) 3 (3 to 5)
*Abbreviations defined in Glossary; RRR, NNT, and CI calculated from data in article.
Evidence of the efficacy of treatments for the common cold are important, given the morbidity and costs to society resulting from coryzal illness. Zinc has antiviral properties in vitro, and following the report of the study of Eby and colleagues (1) in 1984, zinc lozenges have been proposed for the treatment of colds. Since this early trial, several other trials have reported mixed results. The systematic review by Marshall provides an important summary of the evidence from placebo-controlled trials of zinc lozenges.
The main difficulty in summarizing the evidence is the heterogeneity of the data, which limits the ability to pool the results from different studies. Possible sources of heterogeneity are the different viruses, the formulation and dose of zinc, the difficulty of blinding patients to their allocation to treatment or placebo (because of the side effects of zinc), the setting, and the duration of illness before treatment. There is no evidence of benefit after 3 days of treatment and some evidence that fewer patients in the zinc group had cold symptoms at 7 days, but this is based on only 2 studies. Furthermore, the utility of the benefit is questionable because symptoms are usually much less severe at 7 days and any benefit must be balanced against the side effects of zinc. Before the use of zinc loz enges can be recommended in practice, we need more evidence from large randomized controlled trials and a better understanding of the issues surrounding the hetero-geneity of the results.
Paul Little, MBBS
Aldermoor Health Centre
Southampton, England, UK
1. Eby GA, Davis DR, Halcomb WW. Reduction in duration of common colds by zinc gluconate lozenges in a double-blind study. Antimicrob Agents Chemother. 1984; 25:20-4.